Successful use of dupilumab in recalcitrant pediatric atopic dermatitis-like graft-versus-host disease: A case series
Abstract
in an 8-year-old boy who presented with multiple papules, nodules, and lichenified plaques ( A ). Significant improvement was observed after 8 weeks of dupilumab treatment, with complete resolution of the lesions ( B ). As a result, the patient was able to discontinue his other immunosuppressants used for treating his cutaneous GvHD. AD-like , Atopic dermatitis-like; GvHD , graft-versus-host disease.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.